Full history for every metric is available with a Kvantra account
Celadon Pharmaceuticals Plc (CEL.L)
Key financial summary
Financials in GBP| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | £m | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | £m | -6 | -5 | |||||
| Net profit | £m | - | -0 | -1 | -5 | -17 | -7 | -5 |
| EPS reported | £ | -0.12 | -0.08 | |||||
| Operating cashflow per share | £ | -0.10 | -0.10 | |||||
| Capex per share | £ | 0.01 | 0.01 | |||||
| FCF per share | £ | -0.10 | -0.10 | |||||
| Free cash flow | £m | -6 | -6 | |||||
| Net debt | £m | -1 | 0 | |||||
| Book value equity | £m | 3 | 2 | |||||
| Book value per share | £ | 0.05 | 0.04 | |||||
| Number of shares | m | 61.89 | 64.62 | |||||
| DPS (TTM paid) | £ | 0.00 | 0.00 |
Financial summary
Financials in GBP| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 22.54 | 3.80 | |||||
| P/S LTM | x | 949.04 | 70.96 | |||||
| P/FCF LTM | x | -11.27 | -1.61 | |||||
| EV/EBITDA LTM | x | -11.68 | -2.03 | |||||
| EV/Sales LTM | x | 995.15 | 71.08 | |||||
| Earnings Yield LTM | % | -10.03% | -86.09% | |||||
| FCF Yield | % | -8.87% | -62.26% | |||||
| Quality | ||||||||
| ROE | % | -226.09% | -131.82% | |||||
| ROIC | % | -68.65% | -68.65% | |||||
| Operating margin | % | -7908.0% | -7908.0% | |||||
| Gross margin | % | 1.33% | 1.33% | |||||
| FCF/Sales | % | -8417.3% | -8417.3% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +212.50% | +519.05% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -1.34 | -1.20 | |||||
| Net Debt/EBITDA | x | -0.54 | -0.54 | |||||
| EBIT/Net interest | x | -9.92 | -9.92 | |||||
| Net debt/market cap | % | -1.72% | 0.16% | |||||
| Net debt/Equity | x | -0.39 | 0.01 | |||||
| Gross debt/equity | x | 1.49 | 1.97 | |||||
Company overview
Celadon Pharmaceuticals Plc functions as a drug development company, concentrating on the discovery, production, and distribution of cannabinoid compounds for certified medical uses. The firm's primary activity involves the indoor, hydroponic cultivation of THC cannabis, which is then incorporated into medicinal products targeting chronic pain. Furthermore, Celadon intends to broaden its research into cannabinoids, exploring their therapeutic applications not only for persistent pain but also for conditions such as autism and multiple sclerosis. Established in 2018, the company maintains its headquarters in London, United Kingdom.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Celadon Pharmaceuticals Plc (CEL.L)
Celadon Pharmaceuticals Plc functions as a drug development company, concentrating on the discovery, production, and distribution of cannabinoid compounds for certified medical uses. The firm's primary activity involves the indoor, hydroponic cultivation of THC cannabis, which is then incorporated into medicinal products targeting chronic pain. Furthermore, Celadon intends to broaden its research into cannabinoids, exploring their therapeutic applications not only for persistent pain but also for conditions such as autism and multiple sclerosis. Established in 2018, the company maintains its headquarters in London, United Kingdom.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free